核苷类似物单药口服预防肝移植术后乙型病毒性肝炎复发的研究

陈焕伟; 邓斐文; 甄作均

doi:10.3969/j.issn.1674-7445.2014.05.010

核苷类似物单药口服预防肝移植术后乙型病毒性肝炎复发的研究

doi: 10.3969/j.issn.1674-7445.2014.05.010

528000 广东佛山市第一人民医院肝脏外科

基金项目:

佛山市卫生局医学科研课题 2014029

详细信息

通讯作者:
陈焕伟,Email:chwei@fsyyy.com

中图分类号: R617
计量
- 文章访问数: 64
- HTML全文浏览量: 83
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-22
- 刊出日期: 2014-09-15

Research on the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation

Department of Hepatic Surgery, the First People's Hospital of Foshan, Foshan 528000, China

摘要

摘要: 目的探讨核苷类似物单药口服预防肝移植术后乙型病毒性肝炎(乙肝)复发的有效性和安全性。方法回顾性分析1999年10月至2014年4月在广东佛山市第一人民医院行肝移植的32例乙肝相关性疾病患者的临床资料。根据供体来源分为两个阶段。第一阶段为1999年10月至2007年9月的6例无心跳供体肝移植,供肝的乙型肝炎病毒(HBV)血清标志物均为(-),受体术前血清乙型肝炎表面抗原(HBsAg)、乙型肝炎核心抗体(抗-HBc)均为(+),其中2例合并乙型肝炎e抗原(HBeAg)(+),1例合并乙型肝炎e抗体(抗-HBe)(+),5例受体术前血清HBV 脱氧核糖核酸(DNA)>1 000 copies/ml,1例HBV DNA<1 000 copies/ml。给予拉米夫定(100 mg/d)单药口服预防肝移植术后乙肝复发。第二阶段为2011年11月至2014年4月的26例心脏死亡器官捐献供体肝移植(其中1例为肝肾联合移植);供肝血清HBsAg(+)6例、(-)20例,乙型肝炎表面抗体(抗-HBs)(+)15例,HBeAg(+)2例,抗-HBc(+)14例,抗-HBe(+)5例;11例受体术前血清HBV DNA>500 copies/ml,15例HBV DNA<500 copies/ml;25例给予恩替卡韦0.5 mg/d、1例给予替比夫定600 mg/d单药口服预防乙肝复发。结果第一阶段肝移植受体中位随访时间为104个月,全部受体术后血清HBsAg和HBV DNA均转阴,至今未见乙肝复发。第二阶段肝移植受体中位随访时间为50周,20例接受HBsAg(-)供肝,其中1例于术后39周出现一过性HBsAg(+),随后又转阴;另1例肝肾联合移植受体在移植术后28周发生乙肝复发,但血清HBV DNA(-);其中15例采用抗-HBc(+)供体肝移植术后均未见乙肝复发。6例采用HBsAg(+)供体的肝移植受体术后HBsAg均未转阴。所有随访受体均存活,术后均未见HBV DNA复制,亦未发现核苷类似物相关不良反应。结论核苷类似物单药口服预防肝移植术后乙肝的复发是有效和安全的。
- 肝移植 /
- 乙型病毒性肝炎 /
- 复发 /
- 核苷类似物 /
- 单药治疗 /
- 预防
Abstract: Objective To explore the efficacy and safety of the oral nucleoside analogues monotherapy in the prevention of hepatitis B recurrence of patients after liver transplantation (LT). Methods Clinical data of 32 patients with hepatitis B-related disease undergoing LT in the First People's Hospital of Foshan in Guangdong Province from October 1999 to April 2014 were retrospectively analyzed. The patients were divided into two phase groups according to the source of donors. Phase 1 was from October 1999 to September 2007 when 6 patients receiving LT of non-heart-beating donors. The serum hepatitis B virus(HBV) markers of 6 donor livers were all negative. The serum hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) of the recipients before operation were all positive, including 2 cases combined with Hepatitis B e antigen (HBeAg) positive, 1 case combined with hepatitis B virus e antibody (anti-HBe) positive. The serum HBV deoxyribonucleic acid (DNA) of 5 recipients before LT were over 1 000 copies/ml and 1 case were below 1 000 copies/ml. All the patients in phase 1 group were given lamivudine (100 mg/d) monotherapy orally for the prevention of hepatitis B recurrence after LT. Phase 2 was from November 2011 to April 2014 when 26 patients receiving LT of donation after cardiac death including 1 case of combined liver-kidney transplantation. Six of the donor livers were with serum HBsAg positive and 20 cases negative. Fifteen cases were with hepatitis B surface antibody (anti-HBs) positive and 2 cases with HBeAg positive, 14 cases with anti-HBc positive and 5 with anti-HBe positive. The serum HBV DNA of 11 recipients before LT were over 500 copies/ml and 15 cases below 500 copies/ml. Twenty-five cases were given entecarvir 0.5 mg/d and 1 case telbivudine 600 mg/d monotherapy orally for the prevention of hepatitis B recurrence. Results The median follow-up time of the recipients in group phase 1 was 104 months. The serum HBsAg and HBV DNA were both negative in all recipients and no hepatitis B recurrence was observed till now. The median follow-up time of the recipients in group phase 2 was 50 weeks. Twenty cases received donor livers of negative HBsAg, in which 1 case had transient positive HBsAg 39 weeks after LT and became negative later. The patient receiving combined liver-kidney transplantation suffered hepatitis B recurrence 28 weeks after LT but HBV DNA was observed negative. No hepatitis B recurrence was observed in the 15 cases receiving donor livers of positive anti-HBc. Six cases receiving donor livers of positive HBsAg failed to become negative HBsAg after LT. All the follow-up recipients survived. No HBV DNA replication was observed in the recipients after LT. No adverse reaction of related nucleoside analogues was observed. Conclusion It is effective and safe to use nucleoside analogues monotherapy for the prevention of hepatitis B recurrence in patients after LT.
- Liver transplantation /
- Hepatitis B /
- Recurrence /
- Nucleoside analogues /
- Monotherapy /
- Prevention

HTML全文

表 1 第二阶段供体、受体的乙型肝炎病毒血清标志物情况

Table 1. The serum hepatitis B virus markers of donors and recipients in phase2

组别 n HBsAg 抗-HBs HBeAg 抗-HBc 抗-HBe 例数

供体 26 + - + + - 2

+ - - + + 2

+ - - + - 1

+ - - - - 1

- + - + - 6

- + - + + 2

- + - - - 7

- - - - - 4

- - - + + 1

受体 26 + - + + - 3

- + - + + 3

+ - - + - 3

+ - - + + 17

下载: 导出CSV

参考文献(17)

[1]	王向槐,罗红涛.人工肝对乙型病毒性肝炎肝衰竭患者细胞因子的影响[J].器官移植,2012,3(2):112-115,120. http://www.organtranspl.com/browse/detail/qkid/37/id/384.html Wang XH, Luo HT. The influence of artificial liver support systems on serum cytokines in patients with liver failure associated with virus B hepatitis[J]. Organ Transplant,2012,3(2):112-115,120. http://www.organtranspl.com/browse/detail/qkid/37/id/384.html
[2]	汪根树,李华,张琪,等.替比夫定与HBIG联用预防肝移植术后乙型病毒性肝炎复发的疗效[J].器官移植,2011,2(6):314-316,353. http://www.organtranspl.com/browse/detail/qkid/32/id/550.html Wang GS, Li H, Zhang Q, et al. Effect of joint use with telbivudine and hepatitis B immune globulin on prophylaxis of hepatitis B recurrence after liver transplantation[J]. Organ Transplant,2011,2(6):314-316,353. http://www.organtranspl.com/browse/detail/qkid/32/id/550.html
[3]	Jiang L, Jiang LS, Cheng NS, et al. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation[J]. World J Gastroenterol,2009,15(20):2489-2499. doi: 10.3748/wjg.15.2489
[4]	沈中阳,朱志军,邓永林,等.小剂量HBIg联合核苷类似物预防肝移植术后乙肝复发1506例回顾性分析[J].中华肝胆外科杂志,2011,17(5):364-366. Shen ZY, Zhu ZJ, Deng YL, et al. Combination of low-dose HBIg and Nucleoside analogues to prevent recurrent hepatitis B virus after liver transplantation: a retrospective analysis of 1506 cases[J]. Chin J Hepatobiliary Surg,2011,17(5):364-366.
[5]	Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation[J]. Gastroenterology,2011,141(4):1212-1219. doi: 10.1053/j.gastro.2011.06.083
[6]	俞如胜,江艺,吕立志,等.恩替卡韦联合乙肝免疫球蛋白预防肝移植术后乙肝复发[J].中华肝胆外科杂志,2010,16(10):787-788. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331005.htm Yu RS, Jiang Y, Lyu LZ, et al. Prevention of hepatitis B recurrence after liver transplantation with entecavir in combination with HBV immunoglobulin[J]. Chin J Hepatobiliary Surg,2010,16(10):787-788. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201331005.htm
[7]	Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis[J]. Hepatology,2008,48(5):1460-1466. doi: 10.1002/hep.22524
[8]	易述红,蔡常洁,陆敏强,等. 乙肝患者肝移植术后免疫抑制治疗下拉米夫定耐药的发生和治疗[J].中华普通外科杂志,2006,21(11):801-803. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHPZ200611015.htm Yi SH, Cai CJ, Lu MQ, et al. The management of lamivudine resistance in immunocompromised chronic hepatitis B liver transplantation recipient under immunosuppressant therapy[J]. Chin J Gen Surg,2006,21(11):801-803. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHPZ200611015.htm
[9]	马毅,邰强,何晓顺,等.肝移植术后乙型肝炎病毒再感染的预防和处理[J].中华外科杂志,2009,47(16):1209-1212. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY200705021.htm Ma Y, Tai Q, He XS, et al. Prevention and management of hepatitis B virus reinfection after liver transplantation[J]. Chin J Surg,2009,47(16):1209-1212. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY200705021.htm
[10]	Lian JS, Zeng LY, Chen JY, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis[J]. World J Gastroenterol,2013,19(37):6278-6283. doi: 10.3748/wjg.v19.i37.6278
[11]	Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients[J]. Drug Des Devel Ther,2013,8:13-24. http://cn.bing.com/academic/profile?id=2087038270&encoded=0&v=paper_preview&mkt=zh-cn
[12]	Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol,2010,52(2):176-182 doi: 10.1016/j.jhep.2009.11.007
[13]	姜涛,卢实春,赖威,等. HBsAg阳性供肝和HBcAb阳性供肝在肝移植中的应用[J].中华器官移植杂志,2012,33(4):200-204. Jiang T, Lu SC, Lai W, et al. Utilization of liver grafts from hepatitis B surface antigen positive or anti-hepatitis B core positive donors[J]. Chin J Organ Transplant,2012,33(4):200-204.
[14]	Chotiyaputta W, Pelletier SJ, Fontana RJ, et al. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers[J]. Hepatol Int,2010,4(4):707-715. doi: 10.1007/s12072-010-9188-0
[15]	张闻辉,邓永林,郑虹,等.肝移植术后新发乙型肝炎病毒感染的临床分析[J].中华器官移植杂志,2012,33(5):295-298. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002144.htm Zhang WH, Deng YL, Zheng H, et al. Clinical analysis of de novo hepatitis B virus infection after liver transplantation[J]. Chin J Organ Transplant, 2012, 33(5):295-298. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZHYX201210002144.htm
[16]	Lee S, Kwon CH, Moon HH, et al. Antiviral treatment for hepatitis B virus recurrence following liver transplantation[J]. Clin Transplant, 2013, 27(5):E597-E604. doi: 10.1111/ctr.2013.27.issue-5
[17]	李敏如,汪根树,汪国营,等.慢性重型肝炎和肝细胞肝癌患者肝移植围手术期T淋巴细胞亚群及其功能的变化[J/CD]. 中华肝脏外科手术学电子杂志,2013,2(3):153-158. Li MR, Wang GS, Wang GY, et al. Changes of T lymphocyte subset and its function in patients with chronic severe hepatitis or hepatocellular carcinoma during the perioperation of liver transplantation[J/CD]. Chin J Hepat Surg: Electronic Edition,2013,2(3):153-158.